Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2026.10.14
JCR Pharmaceuticals receives marketing authorization in Kuwait for IZCARGO™, a blood-brain barrier-penetrating enzyme replacement therapy for hunter syndrome
2026.10.02
Italfarmaco and JCR Pharmaceuticals enter into exclusive license agreement for the development and potential commercialization of novel investigational therapy for hunter syndrome in the United States, Europe, and Latin America
2026.09.29
2026.09.28
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
2026.09.15
Performance data and annual reports
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
542.00
+6.00
(+1.12%)
Last updated 10/16/2026 at TSE market close
Quarterly results
Annual reports
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media